X0206 3 2019-09-12 0 0001692830 Satsuma Pharmaceuticals, Inc. STSA 0001657768 TAKANASHI KEN C/O SATSUMA PHARMACEUTICALS, INC. 400 OYSTER POINT BOULEVARD, SUITE 221 SOUTH SAN FRANCISCO CA 94080 1 0 1 0 Common Stock, $0.0001 par value 987535 I See Footnote Series A Preferred Stock 0.00 Common Stock 33741 I See Footnote Series B Preferred Stock 0.00 Common Stock 307110 I See Footnote Reflects a 1-for-4.7 reverse stock split effective upon the effectiveness of the registration statement for the Issuer's initial public offering. Shares are held by Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"). Mr. Takanashi, a director of the Issuer, is a director and executive officer of SNBL and its affiliates such that Mr. Takanashi may be deemed to hold the power to direct the disposition and vote of, and therefore to own the shares held by SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL except to the extent of any actual pecuniary interest therein. The filing of this Form 3 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities. Each share of Series A Preferred Stock and Series B Preferred Stock automatically convert into shares of issuer's Common Stock on a 1:1 basis immediately prior to the consummation of Issuer's initial public offering and has no expiration date. /s/ Thomas P. O'Neil as Attorney in Fact for Ken Takanashi, MBA, CPA. 2019-09-12